Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven high-risk hematologic malignancy
• * Acute non-lymphocytic leukemia (ANLL) after induction failure, or in first complete remission (CR) with high-risk features, including any of the following:
• * Stem cell or biphenotypic classification (AML-M0)
• * Erythroleukemia (AML-M6)
• * Acute megakaryocytic leukemia (AML-M7)
• * Cytogenetic markers indicative of poor prognosis
• * Failure to achieve CR after standard induction therapy
• * Acute lymphocytic leukemia (ALL) or ANLL in relapse or second or subsequent remission
• * Chronic myelogenous leukemia (CML) in chronic or accelerated phase
• * Patients with CML in blast crisis are eligible after reinduction chemotherapy places them in chronic phase
• * High-risk ALL in first CR with high risk defined by presence of t(4;11), t(9;22) translocation, hyperleukocytosis (initial WBC greater than 30,000/mm\^3), or failure to achieve CR by day 28 after standard induction
• * No T-cell ALL or t(8;14) positive B-cell ALL in first remission with hyperleukocytosis
• * Myelodysplastic syndrome by peripheral blood smear and bone marrow examination
• * Refractory to medical management OR
• * Cytogenetic abnormalities predictive of transformation into acute leukemia including 5q-, 7q-, monosomy 7, and trisomy 8 OR
• * Evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)
• * Multiple myeloma, non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after autologous stem cell transplantation (SCT)
• * At least 3 months since prior autologous SCT
• * Hodgkin's lymphoma, NHL, or multiple myeloma beyond first CR or primary induction failures whose disease has demonstrated sensitivity to pre-transplantation cytoreduction (defined as greater than 50% reduction in tumor burden)
• * Mantle zone NHL allowed after induction therapy
• * Myeloproliferative disorder that is non-responsive to medical management and requires allografting, unless evidence of grade 3 or worse myelofibrosis on marrow biopsy OR
• Histologically proven acquired severe aplastic anemia (SAA) that is recurrent or unresponsive after anti-thymocyte globulin and/or cyclosporine
• * SAA defined by at least 2 of the following conditions:
• * Granulocyte count less than 500/mm\^3
• * Platelet count less than 20,000/mm\^3
• * Absolute reticulocyte count less than 20,000/mm\^3 after correction for hematocrit
• Ineligible for full ablative conditioning due to any of the following conditions:
• * Prior extensive therapy (more than 2 salvage chemotherapy regimens and/or autologous transplantation)
• * Over age 55 OR
• * Under age 55 with comorbid disease (e.g., suboptimal cardiac, pulmonary, or renal function and/or prior life-threatening infection)
• HLA-A, B, and DR phenotypically identical sibling donor OR
• HLA-A, B, and DR identical genetically matched unrelated donor
• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(8;21) and inv(16) unless failed first-line induction therapy OR
• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(15;17) abnormality unless failed first-line induction therapy OR molecular evidence of persistent disease
• No active CNS disease
• PATIENT CHARACTERISTICS:
• Age:
• 0 to 70
• Performance status:
• Zubrod 0-1
• Karnofsky 80-100%
• Life expectancy:
• At least 3 months
• Hematopoietic:
• See Disease Characteristics
• Hepatic:
• ALT/AST no greater than 4 times normal
• Bilirubin no greater than 2.0 mg/dL
• Renal:
• See Disease Characteristics
• Creatinine clearance at least 50 mL/min
• Cardiovascular:
• See Disease Characteristics
• Shortening fraction or ejection fraction at least 40% of normal for age by echocardiogram or radionuclide scan
• No clinically significant comorbid illnesses (e.g., myocardial infarction or cerebrovascular accident)
• Pulmonary:
• See Disease Characteristics
• FVC and FEV\_1 at least 60% of predicted for age
• DLCO at least 60% of predicted for adults
• Other:
• No severe neurosensory symptoms (i.e., peripheral neuropathy)
• HIV negative
• Active infection allowed if controlled by appropriate drug therapy
• Not pregnant or nursing
• Negative pregnancy test
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified
• Other:
• Recovered from prior therapy
• No concurrent investigational agents unless approved by protocol investigators